Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
[HTML][HTML] Vaccine-induced protection from homologous tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers
MG Pauthner, JP Nkolola, C Havenar-Daughton… - Immunity, 2019 - cell.com
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
The neutralizing antibody response to the HIV-1 Env protein
PL Moore - Current HIV research, 2018 - ingentaconnect.com
Background: A vaccine able to elicit broadly neutralizing antibodies capable of blocking
infection by global viruses has not been achieved, and remains a key public health …
infection by global viruses has not been achieved, and remains a key public health …
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
M Asokan, J Dias, C Liu, A Maximova… - Proceedings of the …, 2020 - National Acad Sciences
Treatment of HIV infection with either antiretroviral (ARV) therapy or neutralizing monoclonal
antibodies (NAbs) leads to a reduction in HIV plasma virus. Both ARVs and NAbs prevent …
antibodies (NAbs) leads to a reduction in HIV plasma virus. Both ARVs and NAbs prevent …
HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop
during natural infection can help guide the rational design of an HIV vaccine. Here, we …
during natural infection can help guide the rational design of an HIV vaccine. Here, we …
Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan
Summary The VH1-2 restricted VRC01-class of antibodies targeting the HIV envelope CD4
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies
Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve
precursors are hindered by unusual features that characterize these Abs, including …
precursors are hindered by unusual features that characterize these Abs, including …
Evaluation of archival HIV DNA in brain and lymphoid tissues
ABSTRACT HIV reservoirs persist in anatomic compartments despite antiretroviral therapy
(ART). Characterizing archival HIV DNA in the central nervous system (CNS) and other …
(ART). Characterizing archival HIV DNA in the central nervous system (CNS) and other …
Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations—Application to HIV-1 quasispecies
Pathogen diversity resulting in quasispecies can enable persistence and adaptation to host
defenses and therapies. However, accurate quasispecies characterization can be impeded …
defenses and therapies. However, accurate quasispecies characterization can be impeded …